These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1699704)

  • 1. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello MJ; Alexander JB; Wisdom C; Camishion RC
    Crit Care Med; 1990 Nov; 18(11):1227-30. PubMed ID: 1699704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
    Spence RK; Norcross ED; Costabile J; McCoy S; Cernaianu AC; Alexander JB; Pello MJ; Atabek U; Camishion RC
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):955-63. PubMed ID: 7849967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
    Stefaniszyn HJ; Wynands JE; Salerno TA
    J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S. clinical studies of the treatment of anemia with fluosol-DA 20%.
    Tremper KK; Cullen BF
    Artif Organs; 1984 Feb; 8(1):19-24. PubMed ID: 6367719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a hemoglobin substitute in the anemic Jehovah's Witness patient.
    Marelli TR
    Crit Care Nurse; 1994 Feb; 14(1):31-8. PubMed ID: 8194324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluosol-DA as a red-cell substitute in acute anemia.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Langdale LA; Krause LM; Rice CL; Chamberlin WH; Moss GS
    N Engl J Med; 1986 Jun; 314(26):1653-6. PubMed ID: 3713771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present status of clinical studies of Fluosol-DA (20%) in Japan.
    Mitsuno T; Ohyanagi H
    Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
    [No Abstract]   [Full Text] [Related]  

  • 10. Is hemoglobin level alone a reliable predictor of outcome in the severely anemic surgical patient?
    Spence RK; Costabile JP; Young GS; Norcross ED; Alexander JB; Pello MJ; Atabek UM; Camishion RC
    Am Surg; 1992 Feb; 58(2):92-5. PubMed ID: 1550312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical use of fluosol-DA in Jehovah's Witness patients.
    Ohyanagi H; Nakaya S; Okumura S; Saitoh Y
    Artif Organs; 1984 Feb; 8(1):10-8. PubMed ID: 6703920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
    Tremper KK; Anderson ST
    Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluosol-DA, a perfluorochemical oxygen-transport fluid for the management of a trochanteric pressure sore in a Jehovah's Witness.
    Brown AS; Reichman JH; Spence RK
    Ann Plast Surg; 1984 May; 12(5):449-53. PubMed ID: 6742725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluosol: therapeutic failure in severe anemia.
    Kale PB; Sklar GE; Wesolowicz LA; DiLisio RE
    Ann Pharmacother; 1993 Dec; 27(12):1452-4. PubMed ID: 8305774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with Fluosol-DA (20%) in the United States.
    Tremper KK; Levine EM; Waxman K
    Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514
    [No Abstract]   [Full Text] [Related]  

  • 16. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
    Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB
    Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of blood and Fluosol-DA for cardiopulmonary bypass.
    Rousou JA; Engelman RM; Anisimowicz L; Dobbs WA
    J Cardiovasc Surg (Torino); 1985; 26(5):447-53. PubMed ID: 4030876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss.
    Police AM; Waxman K; Tominaga G
    Crit Care Med; 1985 Feb; 13(2):96-8. PubMed ID: 3967511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA.
    Tremper KK; Friedman AE; Levine EM; Lapin R; Camarillo D
    N Engl J Med; 1982 Jul; 307(5):277-83. PubMed ID: 7045667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with Fluosol-DA.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Moss GS
    Prog Clin Biol Res; 1983; 122():331-42. PubMed ID: 6878375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.